Chronic Obstructive Pulmonary Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Obstructive Pulmonary Disease (US)
The U.S. treatment landscape for COPD is evolving rapidly as long-acting inhalers and newer therapies reshape prescribing behaviors. Real-world claims data show increasing complexity in treatment initiation and sequencing, with triple-therapy FDCs such as Trelegy gaining momentum over long-acting dual therapies and monotherapies. Newer entrants, including phosphodiesterase inhibitor Ohtuvayre and biologics such as Dupixent and Nucala, are expanding options for moderate to severe disease. Greater use of generic inhaled drugs is also influencing affordability and prescribing choices. Ongoing monitoring of adoption patterns, treatment progression, and brand share is essential.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed COPD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed COPD patients?
- How have Trelegy, Breztri, Ohtuvayre, Dupixent, and Nucala been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of COPD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of COPD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Geography: United States
Real-world data: U.S. pharmacy and medical claims data
Key drugs covered: Trelegy, Breztri, Ohtuvayre, Dupixent, Nucala, albuterol sulfate, Anoro, Stiolto, Spiriva, Yupelri
Key analyses: Brand / therapy usage across longitudinal patient sample; Newly diagnosed patient analysis; Treatment initiation and progression; Line of therapy analysis; Combination therapy analysis; Source of business for recently treated patients; Persistency and compliance analysis.
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
